secwatch / observer
8-K filed January 12, 2023, 6:59 PM ET ticker HRGN CIK 0001563665
leadership confidence high sentiment positive materiality 0.65

Biostage CEO David Green made permanent; new agreement includes $300k salary, stock options

Harvard Apparatus Regenerative Technology, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David Green

Chief Executive Officer
HRGN · Harvard Apparatus Regenerative Technology, Inc.
Effective
2023-01-11
Filed
January 12, 2023, 6:59 PM ET
Effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Green changed role as Chief Executive Officer at Harvard Apparatus Regenerative Technology, Inc..

Action
removed Interim designation
Role
Chief Executive Officer
Exact text from the filing
Effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately
View on SEC.gov

Harvard Apparatus Regenerative Technology, Inc. filing history →

Source: SEC EDGAR
accession 0001563665-23-000004
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.